---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000096"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:54:44.463119+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arvinas amends Yale license, pays $14.95M upfront, $5M in 2025, eliminates minimum royalties

## Summary
- Upfront $14.95M to Yale for amended license and collaboration income from Novartis deal on ARV-766 and AR-V7.
- Additional $5M payment due on first anniversary (June 2025).
- Contingent milestones up to $15M for approval of first two royalty products.
- Ongoing low single-digit royalties on collaboration products; lower single-digit on meaningfully involved products.
- Minimum annual royalties and annual fees eliminated; Yale releases all prior claims.

## SEC filing metadata
- accession: 0001655759-24-000096
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000096/0001655759-24-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000096/arvn-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000096
- JSON: https://secwatch.observer/filing/0001655759-24-000096.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.